MedPath

Mobile Enhancement of Motivation in Schizophrenia

Not Applicable
Completed
Conditions
Schizophrenia
Schizo Affective Disorder
Psychosis
Registration Number
NCT03059771
Lead Sponsor
Indiana University
Brief Summary

Motivation deficits are a strong determinant of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The primary aims of this study are to conduct a pilot study using a randomized design to 1) Test the feasibility and acceptability of a personalized mobile text message intervention, Mobile Enhancement of Motivation in Schizophrenia (MEMS) and to 2) Test the preliminary effectiveness of MEMS compared to a control condition.

Detailed Description

Objectives: Motivation deficits are one of the strongest determinants of poor functional outcomes in people with schizophrenia. Mobile interventions are a promising approach to improving these deficits, as they can provide frequent cues and reinforcements that support goal-directed behavior. The objective of this study is to conduct a pilot study using a randomized design to 1) Test the feasibility and acceptability of a personalized mobile text message intervention, Mobile Enhancement of Motivation in Schizophrenia (MEMS) and to 2) Test the preliminary effectiveness of MEMS compared to a control condition. Methods: Up to forty outpatients with a schizophrenia-spectrum disorder will be recruited. All participants will set individualized recovery goals to complete over an eight-week period; those randomized to receive MEMS will also receive three sets of personalized, interactive text messages each weekday to reinforce and cue goal completion. Before and after the eight-week period, participants in both groups will complete validated measures of motivation. Both groups will also report their goal attainment after eight weeks. Results: It is anticipated that those in the MEMS group will demonstrate greater goal attainment and improvements in motivation compared to the control group. Discussion: This project will test the initial feasibility, acceptability, and effectiveness of a novel intervention for improving one of the most debilitating aspects of schizophrenia.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
59
Inclusion Criteria
  • Schizophrenia-spectrum diagnosis
  • Have a text-message enabled cell-phone
  • Are a current client at a participating community mental health center
  • Are in a non-acute phase of illness or have no medication changes or hospitalizations in the prior 30 days
  • Demonstrate a minimum of moderate motivation impairments according to the Clinical Assessment Interview for Negative Symptoms (CAINS; Kring et al., 2013)
  • Have an English reading level at or above the fourth grade according to the Graded Word List (Pray & Ross, 1969)
Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Goal completionfollow-up (8 weeks)

The percentage of baseline goals participants completed over the eight-week period will be assessed at the follow-up assessment.

Secondary Outcome Measures
NameTimeMethod
Motivation and Pleasure Scale-Self-Report (MAP-SR)baseline and follow-up (8 weeks)

The MAP-SR is a self-report measure 15-item self-report measure that assesses participant's level of motivation and pleasure in several domains, including work and recreational activities. It has been found to be valid and reliable in a schizophrenia-spectrum sample (Llerena, et al., 2013).

Intrinsic Motivation Indexbaseline and follow-up (8 weeks)

The 3-item Intrinsic Motivation Index (Nakagami et al., 2008) from the clinician-rated Quality of Life Scale (Heinrichs et al., 1984) will be used to assess trait-like intrinsic motivation.

Trial Locations

Locations (1)

Midtown Community Mental Health Center

🇺🇸

Indianapolis, Indiana, United States

Midtown Community Mental Health Center
🇺🇸Indianapolis, Indiana, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.